Circulating survivin indicates severe course of juvenile idiopathic arthritis

Clinical and Experimental Rheumatology

Volumn 26, Issue 2, 2008, Pages 373-378

  Galeotti, Lorena ^a,b,c   Adrian, Katrin ^b   Berg, Stefan ^b   Tarkowski, Andrej ^c   Bokarewa, Maria ^c  

^a HOSPITAL GENERAL DE NIÑOS PEDRO DE ELIZALDE   (Argentina)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Inflammation; Juvenile idiopathic arthritis; Prognosis; Survivin

Indexed keywords

ANTINUCLEAR ANTIBODY; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CORTICOSTEROID; INTERLEUKIN 6; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; SERUM AMYLOID A; SURVIVIN;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; BONE TURNOVER; CARTILAGE; CELLULAR DISTRIBUTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; MALE; ONSET AGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RISK ASSESSMENT;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; CHILD; EXTRACELLULAR MATRIX PROTEINS; EXTRACELLULAR SPACE; FEMALE; GLYCOPROTEINS; HUMANS; INTERLEUKIN-6; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SERUM AMYLOID A PROTEIN; SEVERITY OF ILLNESS INDEX;

EID: 43349095137     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. ADIB N, SILMAN A, THOMSON W: Outcome following onset of juvenile idiopathic inflammatory arthritis: I. frequency of different outcomes. Rheumatology (Oxford) 2005; 44: 995-1001.
2. FLATO B, SMERDEL A, JOHNSTON V et al.: The influence of patient characteristics, disease variables, and HLA alleles on the development of radiographically evident sacroiliitis in juvenile idiopathic arthritis. Arthritis Rheum 2002; 46: 986-94.
3. ARGUEDAS O, FASTH A, ANDERSSON-GARE B: A prospective population based study on outcome of juvenile chronic arthritis in Costa Rica. J Rheumatol 2002; 29: 174-83.
4. ADIB N, SILMAN A, THOMSON W: Outcome following onset of juvenile idiopathic inflammatory arthritis: II. predictors of outcome in juvenile arthritis. Rheumatology (Oxford) 2005; 44: 1002-7.
5. OEN K, MALLESON PN, CABRAL DA et al.: Early predictors of longterm outcome in patients with juvenile rheumatoid arthritis: Subset-specific correlations. J Rheumatol 2003; 30: 585-93.
6. SAXENA N, AGGARWAL A, MISRA R: Elevated concentrations of monocyte derived cytokines in synovial fluid of children with enthesitis related arthritis and polyarticular types of juvenile idiopathic arthritis. J Rheumatol 2005; 32: 1349-53.
7. YOKOTA S, MIYAMAE T, IMAGAWA T et al.: Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 818-25.
8. DE BEER FC, MALLYA RK, FAGAN EA, LANHAM JG, HUGHES GR, PEPYS MB: Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982; 2: 231-4.
9. POZNANSKI AK, CONWAY JJ, SHKOLNIK A, PACHMAN LM: Radiological approaches in the evaluation of joint disease in children. Rheum Dis Clin North Am 1987; 13: 57-73.
10. VAN ROSSUM MA, ZWINDERMAN AH, BOERS M et al.: Radiologic features in juvenile idiopathic arthritis: A first step in the development of a standardized assessment method. Arthritis Rheum 2003; 48: 507-15.
11. FLATO B, LIEN G, SMERDEL A et al.: Prognostic factors in juvenile rheumatoid arthritis: A case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 2003; 30: 386-93.
12. VAN ROSSUM M, VAN SOESBERGEN R, DE KORT S et al.: Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol 2003; 30: 825-8.
13. CHOU CT, YANG JS, LEE MR: Apoptosis in rheumatoid arthritis - expression of Fas, Fas-L, p53, and Bcl-2 in rheumatoid synovial tissues. J Pathol 2001; 193: 110-6.
14. BAIER A, MEINECKEL I, GAY S, PAP T: Apoptosis in rheumatoid arthritis. Curr Opin Rheumatol 2003; 15: 274-9.
15. DONN R, ZEGGINI E, SHELLEY E, OLLIER W, THOMSON W: Lack of association between juvenile idiopathic arthritis and fas gene polymorphism. J Rheumatol 2002; 29: 166-8.
16. HAAS JP, FRANK C, HAEFNER R, HERRMANN M, SPATH H, RUDER H: Inverted ratio of m-fas/s-fas expression in early onset pauciarticular juvenile chronic arthritis. Eur J Immunogenet 1999; 26: 325-9.
17. SMOLEWSKA E, BROZIK H, SMOLEWSKI P, BIERNACKA-ZIELINSKA M, DARZYNKIEWICZ Z, STANCZYK J: Apoptosis of peripheral blood lymphocytes in patients with juvenile idiopathic arthritis. Ann Rheum Dis 2003; 62: 761-3.
18. BOKAREWA M, LINDBLAD S, BOKAREW D, TARKOWSKI A: Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R349-58.
19. DUFFY MJ, O'DONOVAN N, BRENNAN DJ, GALLAGHER WM, RYAN BM: Survivin: A promising tumor biomarker. Cancer Lett 2007; 249: 49-60.
20. ALTIERI DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
21. PENNATI M, FOLINI M, ZAFFARONI N: Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007; 28: 1133-9.
22. KRUMREY-LANGKAMMERER M, HAFNER R: Evaluation of the ILAR criteria for juvenile idiopathic arthritis. J Rheumatol 2001; 28: 2544-7.
23. GARE BA, FASTH A: The natural history of juveAile chronic arthritis: a population based cohort study. II. Outcome. J Rheumatol 1995; 22: 308-19.
24. PACKHAM JC, HALL MA: Long-term follow-up of 246 adults with juvenile idiopathic arthritis: Education and employment. Rheumatology (Oxford) 2002; 41: 1436-9.
25. ALTZNAUER F, CONUS S, CAVALLI A, FOLKERS G, SIMON HU: Calpain-1 regulates Bax and subsequent Smac-dependent caspase-3 activation in neutrophil apoptosis. J Biol Chem 2004; 279: 5947-57.
26. SAXNE T, HEINEGARD D: Involvement of nonarticular cartilage, as demonstrated by release of a cartilage-specific protein, in rheumatoid arthritis. Arthritis Rheum 1989; 32: 1080-6.
27. DEN BROEDER AA, JOOSTEN LA, SAXNE T et al.: Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002; 61: 311-8.
28. DRAGOMIR AD, KRAUS VB, RENNER JB et al.: Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. Osteoarthritis Cartilage 2002; 10: 687-91.
29. LARSSON E, ERLANDSSON HARRIS H, LARSSON A, MANSSON B, SAXNE T, KLARESKOG L: Corticosteroid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP. Rheumatology (Oxford) 2004; 43: 428-34.